A multicenter prospective observational study of triple therapy with rabeprazole, amoxicillin and metronidazole for Helicobacter pylori in Japan.
第一作者:
Katsuya,Sugizaki
第一单位:
Drug Fostering and Evolution Coordination Department, Corporate Regulatory Compliance, Safety and Quality Assurance Headquarters, Eisai Co., Ltd., Japan. k-sugizaki@hhc.eisai.co.jp
作者:
主题词
2-吡啶甲基亚硫酰苯咪唑类(2-Pyridinylmethylsulfinylbenzimidazoles);成年人(Adult);老年人(Aged);阿莫西林(Amoxicillin);抗菌药(Anti-Bacterial Agents);抗溃疡病药(Anti-Ulcer Agents);药物疗法, 联合(Drug Therapy, Combination);女(雌)性(Female);螺杆菌感染(Helicobacter Infections);幽门螺杆菌(Helicobacter pylori);人类(Humans);日本(Japan);男(雄)性(Male);甲硝唑(Metronidazole);中年人(Middle Aged);前瞻性研究(Prospective Studies);质子泵抑制剂(Proton Pump Inhibitors);治疗结果(Treatment Outcome)
DOI
10.2169/internalmedicine.51.8510
PMID
23154713
发布时间
2019-06-06
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文